September 16, 2021
Sept. 16, 2021 /PRNewswire/ — Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced that it raised $40 million in an oversubscribed Series A round led by Prime Movers Lab. The funding will enable Elevian to submit an investigational new drug application, scale manufacturing and complete Phase 1 clinical trials for its lead indication of stroke recovery. Additional investors include Bold Capital, Leslie Ventures, John A Kuelbs Family Office and others. As part of the financing, Prime Movers Lab General Partner Brandon Simmons will join Bell on the board of directors. FLG partner Greg Curhan assisted.
Full press release is here.